Free Trial
→ Warning: “DOGE Collapse” imminent (From Altimetry) (Ad)
NASDAQ:ORMP

Oramed Pharmaceuticals 5/9/2024 Earnings Report

Oramed Pharmaceuticals logo
$2.32 +0.05 (+2.20%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$2.32 0.00 (-0.22%)
As of 05/2/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Oramed Pharmaceuticals EPS Results

Actual EPS
$0.04
Consensus EPS
$0.02
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Oramed Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oramed Pharmaceuticals Announcement Details

Quarter
Date
5/9/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Oramed Pharmaceuticals' next earnings date is estimated for Thursday, May 8, 2025, based on past reporting schedules.

Conference Call Resources

Oramed Pharmaceuticals Earnings Headlines

Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
April 28, 2025 | finanznachrichten.de
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
April 28, 2025 | prnewswire.com
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
May 4, 2025 | Altimetry (Ad)
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
April 28, 2025 | globenewswire.com
ORMP: Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 Trial
April 3, 2025 | finance.yahoo.com
Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential
March 15, 2025 | finance.yahoo.com
See More Oramed Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oramed Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oramed Pharmaceuticals and other key companies, straight to your email.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals (NASDAQ:ORMP) engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

View Oramed Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles